KIRhub 2.0· v2

Capivasertib

54f3391d-0fd4-53d9-91c3-cd713633d0e4 · FDA Approved · targets AKT1, AKT2, AKT3

Capivasertib

MeasuredReference

Capivasertib targets PRKACA, P70S6K_RPS6KB1, AKT3. Strongest hallmark effect: evading apoptosis.

Primary targets

PRKACA P70S6K_RPS6KB1 AKT3 PRKX PKACB

Top hallmarks

evading apoptosis3.9k
tumor promoting inflammation3.9k
proliferation3.7k

Top pathways disrupted

pi3k akt mtor signaling7.6k
apoptosis7.2k
g2m checkpoint5.9k

Resistance landscape — Capivasertib

MeasuredReference

3 known oncogenic variants exist on Capivasertib's top targets — see detail for inhibition impact.

PRKACA 1 known variant
- PKA (L206R)
AKT3 2 known variants
- AKT3 (E17K)
- AKT3 (G171R)

Open in new tab